On the evening of March 17, Tianjin Pharmaceutical Co., Ltd. issued an announcement stating that its subsidiary, Hubei Tianjin Pharmaceutical Co., Ltd., received a Drug Registration Certificate for Naloxone Hydrochloride Injection issued by the National Medical Products Administration.

It is understood that this drug is an opioid receptor antagonist. In August 2023, Hubei Jinyao submitted a registration application for this drug to the Center for Drug Evaluation of the National Medical Products Administration and it was accepted. This approval enhances Jinyao Pharmaceutical's pharmaceutical product portfolio and will have a positive impact on the company's expansion in the domestic pharmaceutical market and improved performance.

Articles: Board Office of Tianjin Pharmaceutical Group Co., Ltd., China Securities Journal (China Securities Network)